Revenue segments as reported by the company.

U.S. Healthcare Solutions

International Healthcare Solutions

Pharmaceutical Distribution Services

Other

Intersegment eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, and administrative

Depreciation and amortization

Employee severance, litigation, and other

Goodwill impairment

Impairment of assets

Acquisition, integration, and restructuring expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AmerisourceBergen

AmerisourceBergen Corp. engages in the provision of pharmaceutical products and business solutions that improve access to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical Distribution Services segment distributes an offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, and long-term care and alternate site pharmacies. The Other segment focuses on global commercialization services and animal health, and includes AmerisourceBergen Consulting Services ABCS, World Courier, and MWI. The company was founded by in Emil P. Martini in 1947 and is headquartered in Conshohocken, PA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. The U.S. Healthcare Solutions segment focuses on the distribution of specialty, brand-name, and generic pharmaceuticals. The International Healthcare Solutions segment includes pharmaceutical wholesale, related operations, and global commercialization services. The company was founded by Emil P. Martini in 1947 and is headquartered in Conshohocken, PA.

Cencora Inc

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen becomes Cencora, in alignment with the company's growing global footprint and central role in pharmaceutical access and care.

AmerisourceBergen becomes Cencora, in alignment with the company's growing global footprint and central role in pharmaceutical access and care

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors has elected Werner Baumann and Lauren M. Tyler as new independent directors, effective October 1, 2023. With the election of Mr. Baumann and Ms. Tyler, the Board of Directors will increase from ten to twelve members, ten of whom are independent. “We look forward to welcoming Mr. Baumann and Ms. Tyler to AmerisourceBergen's Board of Directors. Their experience at preeminent m.

AmerisourceBergen Elects Werner Baumann and Lauren Tyler to Its Board of Directors

Walgreens

Walgreens Boots Alliance has sold shares of AmerisourceBergen for initial proceeds of $2.85 billion, which will be used to accelerate the drugstore giant's healthcare strategy.

Walgreens Sells AmerisourceBergen Shares To Raise $1.85 Billion To Pay Down Debt And Accelerate Health Strategy

Walgreens Boots Alliance has sold some AmerisourceBergen Corp's shares for proceeds of about $1.85 billion, the U.S. drugstore chain said on Thursday, further cutting its ownership in the drug distributor to about 16%.

Walgreens sells $1.85 bln of AmerisourceBergen shares, further cutting stake

Drugstore chain Walgreens Boots Alliance Inc. WBA, -1.17% on Thursday said it sold shares of drug distributor AmerisourceBergen Corp. ABC, -0.04% for initial proceeds of $1.85 billion. Walgreens said it planned to use the proceeds it got from the deal largely to pay down debt and to handle general operations.

Walgreens Boots Alliance sells shares of AmerisourceBergen for $1.85 billion

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance sells shares of AmerisourceBergen Corporation for $1.85 billion of initial proceeds.

Walgreens Boots Alliance Sells Shares of AmerisourceBergen Corporation for $1.85 Billion of Initial Proceeds

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Corporation (NYSE: ABC) (the “Company”) announced today a registered public offering of 10.5 million shares of common stock of the Company in connection with Walgreens Boots Alliance Holdings LLC (the “Selling Stockholder”) entering into prepaid variable share forward transactions (the “variable forward transactions”) relating to the Company's common stock with certain counterparties (the “counterparties”). The Company has been advised that,.

AmerisourceBergen Announces Registered Public Offering of Common Shares and Common Share Repurchase

AmerisourceBergen Corporation (NYSE:ABC ) Q3 2023 Earnings Call Transcript August 2, 2023 8:30 AM ET Company Participants Bennett Murphy - SVP, Head of IR and Treasury Steve Collis - Chairman, President and CEO Jim Cleary - EVP and CFO Conference Call Participants Elizabeth Anderson - Evercore ISI Lisa Gill - JP Morgan Eric Percher - Nephron Research Daniel Grosslight - Citi Charles Rhyee - TD Cowen Kevin Caliendo - UBS Eric Coldwell - Baird Jonathan Young - Credit Suisse Dan Clark - Bank of America George Hill - Deutsche Bank Operator Hello, and welcome to today's AmerisourceBergen Q3 Fiscal ‘23 Earnings Call. My name is Jordan, and I'll be coordinating your call today.

AmerisourceBergen Corporation (ABC) Q3 2023 Earnings Call Transcript

Although the revenue and EPS for AmerisourceBergen (ABC) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

AmerisourceBergen (ABC) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

AmerisourceBergen's (ABC) fiscal third-quarter 2023 results benefit from segmental growth. Inflation and unfavorable currency rates hurt operating margin.

AmerisourceBergen (ABC) Beats on Q3 Earnings, Ups '23 EPS View

AmerisourceBergen (ABC) came out with quarterly earnings of $2.92 per share, beating the Zacks Consensus Estimate of $2.83 per share. This compares to earnings of $2.62 per share a year ago.

AmerisourceBergen (ABC) Surpasses Q3 Earnings and Revenue Estimates

Drug distributor AmerisourceBergen raised its full-year profit forecast on Wednesday, as soaring demand for weight-loss drugs and specialty medicines helped soften the blow from a fall in COVID-related drug sales in the third quarter.

AmerisourceBergen forecasts upbeat annual profit as weight-loss drugs lift results

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023 third quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compared to $1.92 in the prior year third quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes ite.

AmerisourceBergen Reports Fiscal 2023 Third Quarter Results

AmerisourceBergen (ABC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for AmerisourceBergen (ABC) This Earnings Season?

AmerisourceBergen has seen a 3x return on investment in the past 3 years, outperforming the market. I think it's a very solid company in pharma and healthcare distribution. Investing in high-quality companies when they are cheap is crucial for maximizing returns. AmerisourceBergen is a conservative and safe option in the pharma and healthcare industry, but has now reached a valuation of where I would consider it a "HOLD".

AmerisourceBergen: Great Company, Wrong Price (Rating Downgrade)

AmerisourceBergen (ABC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AmerisourceBergen (ABC) Reports Next Week: Wall Street Expects Earnings Growth

AmerisourceBergen's (ABC) fiscal third-quarter 2023 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

Is a Beat Likely for AmerisourceBergen (ABC) in Q3 Earnings?

AmerisourceBergen (ABC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

AmerisourceBergen Corporation (ABC) Soars to 52-Week High, Time to Cash Out?

Livent Corp

Perion Network

Looking at three highly-ranked Zacks stocks that have outperformed the market over the last several years, while posting solid growth. All three stocks we dig into also offer investors great value at the moment.

Hunting for Growth Mixed with Value: Buy These 3 Stocks Now

AmerisourceBergen (ABC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will AmerisourceBergen (ABC) Beat Estimates Again in Its Next Earnings Report?

AmerisourceBergen (ABC) could produce exceptional returns because of its solid growth attributes.

AmerisourceBergen (ABC) is an Incredible Growth Stock: 3 Reasons Why

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is AmerisourceBergen (ABC) a Great Value Stock Right Now?

Here is how AmerisourceBergen (ABC) and Hologic (HOLX) have performed compared to their sector so far this year.

Is AmerisourceBergen (ABC) Stock Outpacing Its Medical Peers This Year?

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Third Quarter of Fiscal 2023 on Wednesday, August 2, 2023, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 2, 2023. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executiv.

News for AmerisourceBergen Stock (ABC)